認知症治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Dementia - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0794
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年2月28日
◆ページ数:469
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Dementia – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Dementia – Pipeline Review, H1 2020, provides an overview of the Dementia (Central Nervous System) pipeline landscape.

Dementia is the loss of mental functions such as thinking, memory, and reasoning that is severe enough to interfere with a person’s daily functioning. Symptoms include memory loss, hallucinations, agitation, personality changes and difficulty with coordination and motor functions. Risk factors include age, smoking, obesity, high blood pressure, inflammation and cardiovascular diseases.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Dementia – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Dementia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Dementia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Dementia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 9, 24, 22, 54, 24 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 12 and 4 molecules, respectively.

Dementia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Dementia (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Dementia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Dementia (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Dementia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Dementia (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Dementia (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Dementia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Dementia – Overview
Dementia – Therapeutics Development
Dementia – Therapeutics Assessment
Dementia – Companies Involved in Therapeutics Development
Dementia – Drug Profiles
Dementia – Dormant Projects
Dementia – Discontinued Products
Dementia – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Dementia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Companies, H1 2020 (Contd..3), H1 2020
Products under Development by Companies, H1 2020 (Contd..4), H1 2020
Products under Development by Companies, H1 2020 (Contd..5), H1 2020
Products under Development by Companies, H1 2020 (Contd..6), H1 2020
Products under Development by Companies, H1 2020 (Contd..7), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Dementia - Pipeline by Acadia Pharmaceuticals Inc, H1 2020
Dementia - Pipeline by Actinogen Medical Ltd, H1 2020
Dementia - Pipeline by AcuraStem Inc, H1 2020
Dementia - Pipeline by Adamed Sp zoo, H1 2020
Dementia - Pipeline by ADEL Inc, H1 2020
Dementia - Pipeline by AgeneBio Inc, H1 2020
Dementia - Pipeline by Aibios Co Ltd, H1 2020
Dementia - Pipeline by Alector Inc, H1 2020
Dementia - Pipeline by Alkermes Plc, H1 2020
Dementia - Pipeline by Allergan Plc, H1 2020
Dementia - Pipeline by Alterity Therapeutics Ltd, H1 2020
Dementia - Pipeline by Anavex Life Sciences Corp, H1 2020
Dementia - Pipeline by Annovis Bio Inc, H1 2020
Dementia - Pipeline by Applied Genetic Technologies Corp, H1 2020
Dementia - Pipeline by Aprinoia Therapeutics Inc, H1 2020
Dementia - Pipeline by AriBio, H1 2020
Dementia - Pipeline by Asceneuron SA, H1 2020
Dementia - Pipeline by Axon Neuroscience SE, H1 2020
Dementia - Pipeline by Axovant Gene Therapies Ltd, H1 2020
Dementia - Pipeline by Axsome Therapeutics Inc, H1 2020
Dementia - Pipeline by Biogen Inc, H1 2020
Dementia - Pipeline by BioXcel Therapeutics Inc, H1 2020
Dementia - Pipeline by Boehringer Ingelheim International GmbH, H1 2020
Dementia - Pipeline by Bolder Biotechnology Inc, H1 2020
Dementia - Pipeline by Cennerv Pharma (S) Pte Ltd, H1 2020
Dementia - Pipeline by Cortice Biosciences Inc, H1 2020
Dementia - Pipeline by CSPC NBP Pharmaceutical Co Ltd, H1 2020
Dementia - Pipeline by Cyclerion Therapeutics Inc, H1 2020
Dementia - Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2020
Dementia - Pipeline by Denali Therapeutics Inc, H1 2020
Dementia - Pipeline by DiaMedica Therapeutics Inc, H1 2020
Dementia - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, H1 2020
Dementia - Pipeline by Echo Pharmaceuticals BV, H1 2020
Dementia - Pipeline by EIP Pharma LLC, H1 2020
Dementia - Pipeline by Eisai Co Ltd, H1 2020
Dementia - Pipeline by Eli Lilly and Co, H1 2020
Dementia - Pipeline by Ensol Biosciences Inc, H1 2020
Dementia - Pipeline by Enterin Inc, H1 2020
Dementia - Pipeline by EVER Neuro Pharma GmbH, H1 2020
Dementia - Pipeline by Galimedix Therapeutics Ltd, H1 2020
Dementia - Pipeline by Gismo Therapeutics Inc, H1 2020
Dementia - Pipeline by Guangzhou Magpie Pharmaceutical Co Ltd, H1 2020
Dementia - Pipeline by GW Pharmaceuticals Plc, H1 2020
Dementia - Pipeline by HanAll Biopharma Co Ltd, H1 2020
Dementia - Pipeline by Hemostemix Inc, H1 2020
Dementia - Pipeline by HSRx Group, H1 2020
Dementia - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2020
Dementia - Pipeline by Immungenetics AG, H1 2020
Dementia - Pipeline by ImStar Therapeutics Inc, H1 2020
Dementia - Pipeline by Inhibikase Therapeutics Inc, H1 2020
Dementia - Pipeline by IntraBio Ltd, H1 2020
Dementia - Pipeline by iQure Pharma Inc, H1 2020
Dementia - Pipeline by IRLAB Therapeutics AB, H1 2020
Dementia - Pipeline by Johnson & Johnson, H1 2020
Dementia - Pipeline by Kogenix Therapeutics Inc, H1 2020
Dementia - Pipeline by LA Cell Inc, H1 2020
Dementia - Pipeline by Lachesis Biosciences Ltd, H1 2020
Dementia - Pipeline by Luye Pharma Group Ltd, H1 2020
Dementia - Pipeline by MediPost Co Ltd, H1 2020
Dementia - Pipeline by Mediti Pharma Inc, H1 2020
Dementia - Pipeline by Merz Pharma GmbH & Co KgaA, H1 2020
Dementia - Pipeline by MGC Pharmaceuticals Ltd, H1 2020
Dementia - Pipeline by Neuraltus Pharmaceuticals Inc, H1 2020
Dementia - Pipeline by Neurimmune Holding AG, H1 2020
Dementia - Pipeline by Neurodyn Cognition Inc, H1 2020
Dementia - Pipeline by Neurokine Therapeutics, H1 2020
Dementia - Pipeline by NeuroScientific Biopharmaceuticals Ltd, H1 2020
Dementia - Pipeline by NLS Pharma Group, H1 2020
Dementia - Pipeline by Novartis AG, H1 2020
Dementia - Pipeline by Oligomerix inc, H1 2020
Dementia - Pipeline by Oryzon Genomics SA, H1 2020
Dementia - Pipeline by Otsuka Holdings Co Ltd, H1 2020
Dementia - Pipeline by P2D Inc, H1 2020
Dementia - Pipeline by Pacific Northwest Biotechnology LLC, H1 2020
Dementia - Pipeline by Park Active Molecules, H1 2020
Dementia - Pipeline by Passage Bio Inc, H1 2020
Dementia - Pipeline by Plico Biotech Inc, H1 2020
Dementia - Pipeline by Prevail Therapeutics Inc, H1 2020
Dementia - Pipeline by ProMIS Neurosciences Inc, H1 2020
Dementia - Pipeline by Prothena Corp Plc, H1 2020
Dementia - Pipeline by Psy Therapeutics Inc, H1 2020
Dementia - Pipeline by Resverlogix Corp, H1 2020
Dementia - Pipeline by SanBio Inc, H1 2020
Dementia - Pipeline by Sinfonia Biotherapeutics Inc, H1 2020
Dementia - Pipeline by Stemedica Cell Technologies Inc, H1 2020
Dementia - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2020
Dementia - Pipeline by Suven Life Sciences Ltd, H1 2020
Dementia - Pipeline by SyneuRx International Corp, H1 2020
Dementia - Pipeline by T3D Therapeutics Inc, H1 2020
Dementia - Pipeline by TauRx Therapeutics Ltd, H1 2020
Dementia - Pipeline by Theranexus SAS, H1 2020
Dementia - Pipeline by UniQure NV, H1 2020
Dementia - Pipeline by Voyager Therapeutics Inc, H1 2020
Dementia - Pipeline by Wave Life Sciences Ltd, H1 2020
Dementia - Pipeline by WhanIn Pharmaceutical Co Ltd, H1 2020
Dementia - Dormant Projects, H1 2020
Dementia - Dormant Projects, H1 2020 (Contd..1), H1 2020
Dementia - Dormant Projects, H1 2020 (Contd..2), H1 2020
Dementia - Dormant Projects, H1 2020 (Contd..3), H1 2020
Dementia - Dormant Projects, H1 2020 (Contd..4), H1 2020
Dementia - Dormant Projects, H1 2020 (Contd..5), H1 2020
Dementia - Discontinued Products, H1 2020
Dementia - Discontinued Products, H1 2020 (Contd..1), H1 2020

【掲載企業】

Acadia Pharmaceuticals Inc
Actinogen Medical Ltd
AcuraStem Inc
Adamed Sp zoo
ADEL Inc
AgeneBio Inc
Aibios Co Ltd
Alector Inc
Alkermes Plc
Allergan Plc
Alterity Therapeutics Ltd
Anavex Life Sciences Corp
Annovis Bio Inc
Applied Genetic Technologies Corp
Aprinoia Therapeutics Inc
AriBio
Asceneuron SA
Axon Neuroscience SE
Axovant Gene Therapies Ltd
Axsome Therapeutics Inc
Biogen Inc
BioXcel Therapeutics Inc
Boehringer Ingelheim International GmbH
Bolder Biotechnology Inc
Cennerv Pharma (S) Pte Ltd
Cortice Biosciences Inc
CSPC NBP Pharmaceutical Co Ltd
Cyclerion Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Denali Therapeutics Inc
DiaMedica Therapeutics Inc
Dr. August Wolff GmbH & Co KG Arzneimittel
Echo Pharmaceuticals BV
EIP Pharma LLC
Eisai Co Ltd
Eli Lilly and Co
Ensol Biosciences Inc
Enterin Inc
EVER Neuro Pharma GmbH
Galimedix Therapeutics Ltd
Gismo Therapeutics Inc
Guangzhou Magpie Pharmaceutical Co Ltd
GW Pharmaceuticals Plc
HanAll Biopharma Co Ltd
Hemostemix Inc
HSRx Group
Hyundai Pharmaceutical Co Ltd
Immungenetics AG
ImStar Therapeutics Inc
Inhibikase Therapeutics Inc
IntraBio Ltd
iQure Pharma Inc
IRLAB Therapeutics AB
Johnson & Johnson
Kogenix Therapeutics Inc
LA Cell Inc
Lachesis Biosciences Ltd
Luye Pharma Group Ltd
MediPost Co Ltd
Mediti Pharma Inc
Merz Pharma GmbH & Co KgaA
MGC Pharmaceuticals Ltd
Neuraltus Pharmaceuticals Inc
Neurimmune Holding AG
Neurodyn Cognition Inc
Neurokine Therapeutics
NeuroScientific Biopharmaceuticals Ltd
NLS Pharma Group
Novartis AG
Oligomerix inc
Oryzon Genomics SA
Otsuka Holdings Co Ltd
P2D Inc
Pacific Northwest Biotechnology LLC
Park Active Molecules
Passage Bio Inc
Plico Biotech Inc
Prevail Therapeutics Inc
ProMIS Neurosciences Inc
Prothena Corp Plc
Psy Therapeutics Inc
Resverlogix Corp
SanBio Inc
Sinfonia Biotherapeutics Inc
Stemedica Cell Technologies Inc
Sun Pharma Advanced Research Company Ltd
Suven Life Sciences Ltd
SyneuRx International Corp
T3D Therapeutics Inc
TauRx Therapeutics Ltd
Theranexus SAS
UniQure NV
Voyager Therapeutics Inc
Wave Life Sciences Ltd
WhanIn Pharmaceutical Co Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[認知症治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆